X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2576) 2576
Publication (174) 174
Newsletter (86) 86
Book Chapter (35) 35
Book Review (33) 33
Newspaper Article (27) 27
Magazine Article (13) 13
Trade Publication Article (4) 4
Conference Proceeding (2) 2
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2154) 2154
hyperkalemia (1290) 1290
male (1138) 1138
female (1008) 1008
index medicus (772) 772
hyperkalemia - chemically induced (759) 759
middle aged (667) 667
aged (632) 632
hyperkalemia - drug therapy (601) 601
adult (481) 481
potassium - blood (465) 465
hyperkalemia - etiology (460) 460
potassium (398) 398
risk factors (339) 339
medicine, general & internal (312) 312
urology & nephrology (287) 287
treatment outcome (268) 268
heart failure - drug therapy (260) 260
hyperkalemia - blood (253) 253
spironolactone (247) 247
heart failure (242) 242
hyperkalemia - complications (239) 239
care and treatment (234) 234
hypertension (224) 224
mortality (219) 219
electrocardiography (212) 212
cardiac & cardiovascular systems (208) 208
drug therapy (208) 208
animals (207) 207
aged, 80 and over (204) 204
hyperkalemia - diagnosis (203) 203
hypertension - drug therapy (198) 198
retrospective studies (193) 193
angiotensin-converting enzyme inhibitors - adverse effects (191) 191
hyperkalemia - therapy (189) 189
research (189) 189
therapy (189) 189
angiotensin-converting enzyme inhibitors - therapeutic use (188) 188
drug therapy, combination (188) 188
aldosterone (187) 187
pharmacology & pharmacy (184) 184
mineralocorticoid receptor antagonists - therapeutic use (179) 179
spironolactone - adverse effects (175) 175
spironolactone - therapeutic use (173) 173
potassium - metabolism (156) 156
mineralocorticoid receptor antagonists - adverse effects (151) 151
hyperkalemia - physiopathology (140) 140
renal dialysis (134) 134
renin-angiotensin system - drug effects (130) 130
adolescent (129) 129
diuretics - therapeutic use (128) 128
kidney diseases (126) 126
complications and side effects (124) 124
hyperkalemia - epidemiology (122) 122
patients (120) 120
heart-failure (119) 119
management (119) 119
abridged index medicus (117) 117
risk (114) 114
kidney failure, chronic - complications (113) 113
time factors (112) 112
diabetes (111) 111
chronic kidney-disease (108) 108
diuretics - adverse effects (105) 105
chronic kidney disease (104) 104
health aspects (104) 104
hypokalemia (103) 103
angiotensin (102) 102
blood pressure (102) 102
pediatrics (102) 102
hyperkalaemia (100) 100
child (98) 98
hemodialysis (97) 97
chronic kidney failure (96) 96
dose-response relationship, drug (96) 96
eplerenone (96) 96
medicine & public health (96) 96
creatinine - blood (92) 92
infant (91) 91
insulin (91) 91
diuretics (90) 90
dosage and administration (90) 90
analysis (89) 89
sodium (88) 88
nephrology (87) 87
clinical trials (86) 86
follow-up studies (86) 86
drugs (84) 84
hyperkalemia - prevention & control (84) 84
peripheral vascular disease (84) 84
serum potassium (84) 84
prospective studies (83) 83
heart failure - complications (82) 82
insulin - therapeutic use (82) 82
blood-pressure (81) 81
drug interactions (81) 81
infant, newborn (81) 81
aldosterone - blood (80) 80
glomerular filtration rate (80) 80
blood pressure - drug effects (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2456) 2456
German (82) 82
French (65) 65
Spanish (30) 30
Japanese (24) 24
Italian (15) 15
Russian (14) 14
Polish (13) 13
Hungarian (8) 8
Danish (6) 6
Finnish (4) 4
Norwegian (4) 4
Portuguese (4) 4
Chinese (3) 3
Serbian (3) 3
Dutch (2) 2
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Korean (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 24, pp. 2267 - 2276
This trial tested single versus dual inhibition of the renin–angiotensin–aldosterone system in ADPKD. ACE-inhibitor monotherapy controlled blood pressure in... 
RECEPTOR BLOCKER | MEDICINE, GENERAL & INTERNAL | RENIN | RAMIPRIL | COMBINATION THERAPY | ACE-INHIBITOR | BLOOD-PRESSURE CONTROL | PROTEINURIA | PROGRESSION | ALDOSTERONE SYSTEM | CONVERTING-ENZYME | Benzoates - therapeutic use | Renal Insufficiency, Chronic - etiology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Hypertension - drug therapy | Male | Aldosterone - urine | Hypertension - etiology | Renal Insufficiency, Chronic - drug therapy | Young Adult | Glomerular Filtration Rate - drug effects | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Polycystic Kidney, Autosomal Dominant - drug therapy | Benzimidazoles - therapeutic use | Albuminuria - etiology | Double-Blind Method | Disease Progression | Kidney Failure, Chronic - prevention & control | Adolescent | Polycystic Kidney, Autosomal Dominant - physiopathology | Polycystic Kidney, Autosomal Dominant - complications | Treatment outcome | Care and treatment | Lisinopril | Analysis | Dosage and administration | Polycystic kidney disease | Telmisartan | Hypertension | End-stage renal disease | Excretion | Inhibitor drugs | Kidneys | Polycystic kidney | Diabetes mellitus | Albumin | Aldosterone | Glomerular filtration rate | Quality of life | Hyperkalemia | Renin | Pain | Angiotensin | Blood pressure | Kidney diseases | Drug therapy | Angiotensin II
Journal Article
Diabetologia, ISSN 0012-186X, 12/2011, Volume 54, Issue 12, pp. 2978 - 2986
The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a... 
Type 2 diabetes | Medicine & Public Health | Human Physiology | Metabolic Diseases | Internal Medicine | Diabetic nephropathy | Macroproteinuria | Angiotensin receptor blocker | CONTROLLED-TRIAL | METAANALYSIS | HEART-FAILURE | RISK | CONVERTING-ENZYME-INHIBITORS | MICROALBUMINURIA REDUCTION | TELMISARTAN | DISEASE | ENDOCRINOLOGY & METABOLISM | CANDESARTAN | HYPERTENSION | Kidney Failure, Chronic - mortality | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Drug Therapy, Combination - adverse effects | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Imidazoles - therapeutic use | Kidney Failure, Chronic - drug therapy | Treatment Outcome | Antihypertensive Agents - therapeutic use | Diabetic Nephropathies - mortality | Proteinuria - drug therapy | Diabetes Mellitus, Type 2 - mortality | Creatinine - blood | Hyperkalemia - chemically induced | Drug Therapy, Combination - statistics & numerical data | Tetrazoles - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Asian Continental Ancestry Group - statistics & numerical data | Caregivers | Medical colleges | Diabetics | Enzyme inhibitors | Analysis | Angiotensin converting enzyme | Angiotensin | Diabetic nephropathies | Heart attack
Journal Article
Circulation Research, ISSN 0009-7330, 03/2015, Volume 116, Issue 6, pp. 960 - 975
Blockers of the renin–angiotensin–aldosterone system (RAAS), that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1... 
remodeling | gender | aldosterone | AT2 receptor | hyperkalemia | resistant hypertension | receptor | renin | primary aldosteronism | reactive oxygen species | angiotensin | angiotensin-(1-7) | prorenin | angiotensin-(1–7) | CARDIAC & CARDIOVASCULAR SYSTEMS | BLOOD-PRESSURE RESPONSES | PLASMA-RENIN | CONVERTING ENZYME-INHIBITORS | CORONARY VASCULAR BED | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | II TYPE-2 RECEPTOR | HEMATOLOGY | MYOCARDIAL-INFARCTION | AT 2 receptor | CELL MINERALOCORTICOID RECEPTORS | SEX-DIFFERENCES | CONGESTIVE-HEART-FAILURE | Antihypertensive Agents - pharmacology | Drugs, Investigational - pharmacology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Drugs, Investigational - therapeutic use | Endothelium, Vascular - drug effects | Hypertension - drug therapy | Male | Ion Channels - physiology | Sex Chromosomes | Molecular Targeted Therapy | Gonadal Steroid Hormones - physiology | Vasoconstriction - physiology | Drug Interactions | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hyperaldosteronism - physiopathology | Female | Hypertension - genetics | Drug Evaluation, Preclinical | Drug Resistance | Precision Medicine | Aldosterone - physiology | Endothelium, Vascular - physiopathology | Hyperaldosteronism - genetics | Mice, Transgenic | Renin-Angiotensin System - genetics | Renin-Angiotensin System - physiology | Clinical Trials as Topic | Sex Characteristics | Antihypertensive Agents - therapeutic use | Vasoconstriction - drug effects | Hyperaldosteronism - drug therapy | Hypertension - physiopathology | Mice, Knockout | Mineralocorticoid Receptor Antagonists - therapeutic use | Animals | Renin-Angiotensin System - drug effects | Mice | Therapeutic Equivalency
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 3, pp. 211 - 221
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 20, pp. 1892 - 1903
Journal Article
JAMA, ISSN 0098-7484, 09/2015, Volume 314, Issue 9, pp. 884 - 894
Journal Article